PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | Substitute for for | m 1449A/PTO | | | Complete if Known | | |
|--|--------------------|-------------------|--------|---------|------------------------|------------------|--|
| | • | | 001 | (DF | Application Number | 10/505,252 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | | Filing Date | August 19, 2004 | |
| | | | | | First Named Inventor | Francois Romagne | |
| | (u | se as many sheets | as nec | essary) | Art Unit | 1614 | |
| | | | | | Examiner Name | | |
| | Sheet | 1 | of | 2 | Attorney Docket Number | INN-112 | |

| | | | U.S. PATENT DO | OCUMENTS | |
|-----------------------|---------------|--|--------------------------------|---|---|
| Examiner Initials* | Cite No. 1 | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| 08 | U1 | US- 5,902,793 | 05-11-1999 | Bloom B.R. et al. | ALL |
| | U2 | | | | |
| | U3 | | <u> </u> | | |
| | U4 | US- | | | |
| | U5 | US- | | | · |
| | U6 | US- | | | |
| | U7 | US- | | | |
| | U8 | US- | | | |
| | U9 | US- | | | |

| | | FOREIGN | PATENT DOCU | JMENTS | | | |
|--------------------|--------------------------|---|------------------|---|---|----------------|-----------|
| | | Foreign Patent Document | Publication Date | Name of Patentee or | Pages, Columns, Lines, | | |
| Examiner Initials* | Cite No. ¹ | Country Code 3 - Number 4 - Kind Code5 (if known) | MM-DD-YYYY | Applicant of Cited Document | Where Relevant Passages or Relevant Figures Appear | τ [¢] | |
| | | | | Institut National de la Santé et de la | | | Duplicat |
| | FT | WO 00/12516 A | 03-09-2000 | Recherche Médical | ALL | | Dapricocc |
| | F2 | | | | | | |
| | F3 | | | | | | |
| | F4 | | | | <u> </u> | | |
| | F5 | | | | | <u> </u> | |
| | F6 | | | | | | |
| | F7 | | | | | | |

| Examiner | 111111111111111111111111111111111111111 | Date | 11 1100 2001 |
|-----------|---|------------|--------------|
| Signature | //www x | Considered | 14 MAR. 2006 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that Issued the document, by the two-letter code (MPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under MPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

2

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

| Complete if Known | | | | | | |
|------------------------|------------------|--|--|--|--|--|
| Application Number | 10/505,252 | | | | | |
| Filing Date | August 19, 2004 | | | | | |
| First Named Inventor | Francois Romagne | | | | | |
| Group Art Unit | 1614 | | | | | |
| Examiner Name | | | | | | |
| Attorney Docket Number | INN-112 | | | | | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|---------------|---|----|
| Examiner Initials* | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| 9 | R1 | KUNZMANN, Volker et al. "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma." Blood (2000), 96(2):384-392. | |
| od | R2 | DATABASE MEDLINE 'Online', February 1997 (1997-02), L1 X. et al. "Establishment of a novel culture system for specific expansion of human gamma delta T cell and study of its biological properties" Database accession no. NLM9596941 X002223786 (abstract) & ZHONGHUA Yi Xue Za Zhi. China Feb. 1997, vol. 77, no. 2, February 1997 (1997-02), pages 111-114. | |
| | R3 | | - |
| | R4 | | - |
| | R5 | | - |
| | R6 | | _ |
| | R7 | | _ |
| | R8 | | |
| | R9 | | |
| | R10 | | |
| | R11 | | |
| | R12 | | |

| Examiner Signature | allum | Date Considered | 14 MAR. 2006 |
|--|-------|---|-------------------------------------|
| AND A SALES OF THE | | tation is in another seem with MARCH COO. Draw line the | even eitation if not in conformance |

*EXAMINER: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for for | m 1449A/PTO | | | Complete if Known | | |
|--------------------|-------------------------|------------|--------|------------------------|------------------|--|
| | | | 25 | Application Number | 10/505,252 | |
| | ATION DISC ENT BY AP | | | Filing Date | August 19, 2004 | |
| SIAIEWI | ENIBIAF | PLICA | N I | First Named Inventor | Francois Romagne | |
| (4 | ise as many shee | ts as nece | ssary) | Art Unit | 1614 | |
| | | | | Examiner Name | | |
| Sheet | 1 | of | 3 | Attorney Docket Number | INN-112 | |

| | | | U.S. PATENT DO | CUMENTS | |
|-----------------------|---------------|--|--------------------------------|---|---|
| Examiner Initials* | Cite No. 1 | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| wo | U1 | US- 5,639,653 | 06-17-1997 | Bloom B.R. et al. | ALL |
| | U2 | | | | |
| | U3 | | | | |
| | U4 | | | | |
| | U5 | | | | |
| | U6 | | | | |
| | U7 | | | | |
| | U8 | | | | |
| | U9 | | | | |

| | | FOREIGN | PATENT DOCU | JMENTS | | | |
|--------------------|--------------------------|---|--------------------------------|---|---|----------------|-----------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ | |
| 00 | F1 | WO 99/46365 | 09-16-1999 | Emory University | ALL | | 5 6. |
| ay | F2 | WO 00/12516 | 03-09-2000 | Institut National de la Sante et de la Recherche Medicale | ALL | × | 6660723 |
| 00 | F3 | WO 00/12519 | 03-09-2000 | Institut National de la Sante et de la Recherche Medicale | ALL | × | english eg Abstr only |
| az | F4 | WO 95/20673 | 08-03-1995 | Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale | ALL | , _ | Abstr |

Examiner Signature Date Considered 14 MAR. 2006

*EXAMINER: Initial if reference considered, whether or not cibation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nich of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is anached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Offica: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

| Substitute for form 1449B/PTO | Complete if Known | | | | |
|-------------------------------|-------------------|------------|----------|------------------------|------------------|
| | RMATION | - | OCHDE | Application Number | 10/505,252 |
| | | | | Filing Date | August 19, 2004 |
| STATEMENT BY APPLICANT | | | | First Named Inventor | Francois Romagne |
| lu | se as many shee | le se nor | ·accan/) | Group Art Unit | 1614 |
| Įu. | so as many snec | 13 43 1100 | cosury, | Examiner Name | |
| Sheet | 2 | of | 3 | Attorney Docket Number | INN-112 |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|---------------|--|----|
| Examiner Initials* | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| W | R1 | BEHR, C. et al. "Plasmodium falciparum stimuli for human γδ T cells are related to phosphorylated antigens of mycobacteria" Infection and Immunity, 1996, pp. 2892-2896, Vol. 64, No. 8. | |
| ox | R2 | BORDIGNON, C. et al. "Cell therapy: achievements and perspectives" Haematologica, 1999, pp. 1110-1149, Vol. 84. | |
| .00 | R3 | CONSTANT, P. et al. "Stimulation of Human γδ T Cells by Nonpeptidic Mycobacterial Ligands" Science, 1994, pp. 267-270, Vol. 264. | |
| or | R4 | CONSTANT, P. et al. "The Antituberculous Mycobacterium bovis BCG Vaccine Is an Attenuated Mycobacterial Producer of Phosphorylated Nonpeptidic Antigens for Human γδ T Cells" Infection and Immunity, 1995, pp. 4628-4633, Vol. 63, No. 12. | |
| $\langle \rangle$ | R5 | DAVISSON, V.J. et al. "Synthesis of Allylic and Homoallylic Isoprenoid Phyrophosphates" Methods in Enzymology, 1975, pp. 130-144, Vol. 110. | |
| 00 | R6 | DAVISSON, V.J. et al. "Phosphorylation of Isoprenoid Alcohols" J. Org. Chem., 1986, pp. 4768-4779, Vol. 51. | |
| 00 | R7 | FOURNIE, J.J. et al. "Stimulation of γδ T cells by phosphoantigens" Res. Immunol. 66th Forum in Immunology, 1996, pp. 338-347, Vol. 147. | |
| od | R8 | HINTZ, M. et al. "Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human $\gamma\delta$ T cells in <i>Echerichia coli</i> " FEBS Lett., 2001, pp. 317-322, Vol. 509. | |
| az | R9 | KNORRE, D.G. et al. "General Method for the Synthesis of ATP Gamma-Derivatives" FEBS Letters, 1976, pp. 105-108, Vol. 70, No. 1. | |
| 07 | R10 | MUEHLBACHER, M. et al. "Isopentenyl-diphosphate isomerase: Inactivation of the Enzyme with Active-Site-Directed Irreversible Inhibitors and Transition-State Analogues" Biochemistry, 1988, pp. 7315-7328, Vol. 27. | |
| oz | R11 | POCCIA, F. et al. "CD94/NKG2 Inhibitory Receptor Complex Modulates Both Anti-Viral and Anti-Tumoral Responses of Polyclonal Phosphoantigen-Reactive Vγ9Vδ2 T Lymphocytes" J. Immunol., 1997, pp. 6009-6017, Vol. 159. | |

Examiner Date Signature MAR. 2006 Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Attorney Docket Number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Complete if Known **Application Number** 10/505,252 Filing Date August 19, 2004 First Named Inventor Francois Romagne **Group Art Unit** 1614 **Examiner Name**

INN-112

(use as many sheets as necessary) Sheet

R16

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials* No. number(s), publisher, city and/or country where published. POCCIA, F. et al. (1997) "γδ T cell activation or anergy during infections: The role of nonpeptidic TCR ligands and HLA class I moleculrs" J. Leukocyte Biol., September 1997, pp. 287-291, Vol. 62. R12 POOUET, Y. et al. "A novel nucleotide-containing antigen for human blood γδ T lymphocytes" Eur. J. Immunol., 1996, pp. 2344-2349, Vol. 26. **R13** POQUET, Y. et al. "High-pH Anion-Exchange Chromatographic Analysis of Phosphorylated Compounds: Application to Isolation and Characterization of Nonpeptide Mycobacterial Antigens" Anal. Biochem., 1996, pp. 119-126, Vol. 243. **R14** SCIAMMAS, R. et al. "TCR yo cells and viruses" Microbes and Infection, 1999, pp. 203-212, Vol. 1. **R15**

| Evaminor | 1 /1.// . | | 10-4 |
|-------------|------------------------------|---------|---|
| Examiner | 11/1/11/100 | | I Date I |
| Signature | 1 <i>1/12/1 1/1/1/1</i> / | 1 ~ > X | 1 |
| i Signature | 1 <i>1781</i> 11 11 11 11 11 | | Considered 1/4 MHK . 2006 |
| | | | Considered / / / / / / / |
| | | () | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

| Substitute for fo | Substitute for form 1449A/PTO | | | Complete if Known | | |
|---|-------------------------------|-------------|--------------|------------------------|------------------|--|
| INFORM | ATION DIC | CL OCLI | DE / 01/ | Coplication Number | 10/505, 252 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | MT / | Fillen Date | August 19, 2004 | |
| SIAILII | S MAR a a l | | | | Francois Romagne | |
| (4 | use as many shee | ets as nece | ssary) 🖫 | Art Unit | 1651 | |
| | | | C HOUSE COME | Examiner Name | Allison M. Ford | |
| Sheet | 1 | of | 2 | Attorney Docket Number | INN-112 | |

| U.S. PATENT DOCUMENTS | | | | | | | | |
|---|----|--------------|------------|----------------|-----|--|--|--|
| Examiner Cite Document Number Publication Date Name of Patentee or Applicant Relevant Passa known) Document Number - Kind Code* (if MM-DD-YYYY of Cited Document Figures | | | | | | | | |
| 02 | U1 | US-6,660,723 | 12-09-2003 | Belmant et al. | All | | | |
| | U2 | US- | | | | | | |
| | U3 | US- | | | | | | |
| | U4 | US- | | | | | | |
| | U5 | US- | | | | | | |
| | U6 | US- | | | | | | |
| | U7 | US- | | | | | | |
| | U8 | US- | | | | | | |
| | U9 | US- | | | | | | |

| | | FOREIGN | PATENT DOC | JMENTS | | | |
|-----------------------|---------------|---|--------------------------------|---|---|----------|----------------------|
| Examiner Initials* | Cite No. 1 | Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | r• | |
| | F1- | WQ 00/12516 | - 03-09-2000 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | All | | Duplicaz Duplicaz |
| | F2 | WO 99/46365 | 09-16-1909 — | EMORY UNIVERSITY | All | <u> </u> | TANK |
| OX | F3 | WO 01/75072 | 11-11-2001 | HEMOSOL INC. | All | | Daymou |
| | F4 | | | | | | |
| | F5 | | | | | | |
| | F6 | | | | | | |
| | F7 | | | | | | |

Examiner Date 14 MAR. 2006 Signature Considered

*EXAMINER: Initial if reference considered, whether or not chation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (MPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under MPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

MAR n & żójóg t of 1995, no pergay Under the Paperwork Reduction act of control number. control number.

of

2

are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/P 10 Appendix OF INFORMATION DISCLOSURE STATEMENT BY APPLICANT

2

Sheet

(use as many sheets as necessary)

| Complete if Known | | | | |
|------------------------|------------------|--|--|--|
| Application Number | 10/505, 252 | | | |
| Filing Date | August 19, 2004 | | | |
| First Named Inventor | Francois Romagne | | | |
| Group Art Unit | 1651 | | | |
| Examiner Name | Allison M. Ford | | | |
| Attorney Docket Number | INN-112 | | | |

| | | NON PATENT LITERATURE DOCUMENTS | _ |
|-----------------------|---------------|--|----|
| Examiner Initials* | Cite No. ' | include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| 00 | R1 | JANSSEN, O. et al. "T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor γδ" T cells", <i>The Journal of Immunology</i> , January 1, 1991, pp. 35-39, Vol. 146, No. 1. | |
| 9 | R2 | LOPEZ, R.D. et al. "CD2-mediated IL-12-dependent signals render human yŏ-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies", Immunobiology, December 1, 2000, pp. 3827-3837, Vol. 96, No. 12. | |
| 00 | R3 | YAMAGUCHI, T. et al. "A simple method for the propagation and purification of γδT cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2", Journal of Immunological Methods, 1997, pp. 19-28, Vol. 205. | |
| | R4 | | |
| | R5 | | |
| | R6 | | |
| | R7 | | |
| | R8 | | |
| | R9 | | ļ |
| | R10 | | |
| | R11 | | |
| | R12 | | |
| | R13 | | |

| | | | |
|-----------------------|------|-----------------------|----------|
| Examiner Signature | unx | Date Considered 14 | MAR 2006 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 US.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will large described in individual case. An comments on the amount of time you require to complete this application. Committen to gave the day 35 U.S.C. 122 and 37 CFR 1.14. This contection is caused to take 2 hours to complete, including gautering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\INN\112\SB-08.doc/DNB/gyl